Table IX. Median time to highest decrease and re-increase in CA19-9 levels in patients with pancreatic ductal adenocarcinoma treated with gemcitabine plus nab-paclitaxel, based on the pre-chemotherapy risk and effectiveness.

*In the pre-low-risk and ineffective group and pre-high-risk and ineffective group, there were 8 (31%) and 17 (59%) patients with no improvement in CA19-9, respectively. Therefore, in the pre-high-risk and ineffective group, the values of time to most decreased CA19-9 level and time to reincreased CA19-9 level were reversed.